BTC-001

BTC-001 is a dual-acting small molecule opioid ligand being developed for the treatment of chronic pain. It functions as a bifunctional modulator of the opioid system, acting as an agonist at the Mu Opioid Receptor (MOR) and an antagonist at the Delta Opioid Receptor (DOR). This dual mechanism is designed to provide potent analgesic effects while potentially reducing the development of tolerance and opioid-induced side effects, such as respiratory depression and physical dependence, which are commonly associated with traditional MOR-selective agonists. The drug is currently being evaluated in clinical trials to establish its safety and efficacy profile in patients suffering from various chronic pain conditions.